ESMO's tumor DNA scale seeks to personalize medicines

21 August 2018

The European Society for Medical Oncology (ESMO) has made a contribution to the advancement of precision medicines through a new tumor DNA scale to help match cancer patients to the appropriate targeted medicines.

Agreed by specialists in Europe and North America, the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) is promised to simplify and standardize choices for targeted cancer treatment. It has been published this week in the Annals of Oncology.

Fabrice André, chair of the ESMO Translational Research and Precision Medicine Working Group which initiated this project, said: “Doctors receive a growing amount of information about the genetic make-up of each patient’s cancer, but this can be difficult to interpret for making optimal treatment choices.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK